Pomalidomide for Kaposi Sarcoma
Trial Summary
What is the purpose of this trial?
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but certain medications are prohibited, such as those containing zidovudine and strong inhibitors of specific enzymes. It's important to discuss your current medications with the trial team to ensure there are no interactions.
What data supports the effectiveness of the drug pomalidomide for treating Kaposi Sarcoma?
Is pomalidomide safe for humans?
Pomalidomide, used for treating Kaposi Sarcoma, is generally considered safe in humans, but like any medication, it can have side effects. It is an oral drug that modifies the immune system and has been approved by the FDA for its anti-angiogenic activity (reducing blood vessel growth in tumors).678910
What makes the drug pomalidomide unique for treating Kaposi Sarcoma?
Pomalidomide is unique for treating Kaposi Sarcoma because it is an oral drug that modulates the immune system, making it suitable for patients with or without HIV. It offers a new option for those with advanced disease who have already tried other treatments, and it can be administered in resource-limited settings.12111213
Research Team
Samantha L Vogt
Principal Investigator
AIDS Malignancy Consortium
Eligibility Criteria
Adults with confirmed Kaposi Sarcoma (KS) and measurable disease, who understand the trial and consent to participate. They must have proper organ function, a life expectancy over 6 months, stable HIV treatment if positive, and agree to REMS program for drug safety. Pregnant women, those with certain heart conditions or mental illnesses that affect compliance, prior use of similar drugs like thalidomide or active infections are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pomalidomide orally once daily on days 1-21, repeated every 28 days for up to 12 cycles
Extended Treatment
Participants with complete or partial response continue pomalidomide for an additional 12 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Pomalidomide
Pomalidomide is already approved in United States, European Union, Canada, Japan for the following indications:
- Multiple myeloma
- Kaposi's sarcoma
- Multiple myeloma
- Kaposi's sarcoma
- Multiple myeloma
- Kaposi's sarcoma
- Multiple myeloma
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor